GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
X

Xunfei Healthcare Technology Co 2506.HK · HKD

N/A · HKEX · 🇭🇰 Hong Kong

Compare

68.20

+4.92%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥915.0m

FY2021FY2025

Net income

−CN¥64.8m

FY2021FY2025

Free cash flow

−CN¥156.4m

FY2021FY2025

Shareholders' equity

CN¥896.6m

FY2021FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021
RevenueCN¥915.0mCN¥623.7mCN¥472.5mCN¥400.9mCN¥372.5m
Gross profitCN¥461.6mCN¥343.4mCN¥267.4mCN¥196.0mCN¥187.7m
Research and developmentCN¥245.3mCN¥231.0mCN¥224.3mCN¥205.3mCN¥159.8m
Operating income−CN¥81.7m−CN¥140.9m−CN¥157.8m−CN¥206.9m−CN¥102.7m
Net income−CN¥64.8m−CN¥112.7m−CN¥123.1m−CN¥160.9m−CN¥89.4m
Diluted earnings per share-0.54-0.93-1.02-1.33-0.74

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Total assetsCN¥2.31bnCN¥2.09bnCN¥1.24bnCN¥874.8mCN¥1.01bn
Cash and short-term investmentsCN¥364.8mCN¥676.8mCN¥167.5mCN¥210.7m—
Total liabilitiesCN¥1.42bnCN¥1.15bnCN¥738.8mCN¥584.9mCN¥516.8m
DebtCN¥138.3mCN¥69.4mCN¥504,000——
Shareholders' equityCN¥896.6mCN¥939.9mCN¥498.8mCN¥289.9mCN¥426.6m
Shares outstanding121m121m121m121m121m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021
Cash from operations−CN¥43.0m−CN¥134.1m−CN¥314.3m−CN¥96.8m−CN¥52.7m
Capital spending−CN¥113.4m−CN¥33.0m−CN¥36.5m−CN¥12.8m−CN¥28.6m
Free cash flow−CN¥156.4m−CN¥167.2m−CN¥350.8m−CN¥109.6m−CN¥81.3m

Latest quarters

By quarter end

Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023
RevenueCN¥616.4mCN¥298.6mCN¥428.9mCN¥194.8mCN¥307.2m
Gross profitCN¥307.8mCN¥153.9mCN¥240.4mCN¥103.0mCN¥181.2m
Operating incomeCN¥13.6m−CN¥95.3m−CN¥4.0m−CN¥137.0m−CN¥50.3m
Net incomeCN¥9.3m−CN¥74.1m−CN¥2.5m−CN¥110.2m−CN¥40.2m
Diluted earnings per share0.08-0.61-0.02-0.91-0.33
Cash from operations——−CN¥113.0m−CN¥113.0m−CN¥267.0m
Capital spending——−CN¥28.0m−CN¥16.0m−CN¥31.0m
Free cash flow——−CN¥141.0m−CN¥129.0m−CN¥298.0m
Total assetsCN¥2.31bnCN¥2.32bnCN¥1.78bnCN¥1.08bn—
Cash and short-term investmentsCN¥364.8mCN¥743.9mCN¥575.0mCN¥86.6m—
DebtCN¥138.3mCN¥214.3mCN¥59.0mCN¥17.0m—
Shareholders' equityCN¥896.6mCN¥881.7mCN¥798.6mCN¥337.6m—

Financial ratios

Data as of 13 Oct 2026

FY2025FY2024FY2023FY2022FY2021
Gross margin50.5%55.1%56.6%48.9%50.4%
Operating margin-9.2%-22.6%-33.4%-51.6%-27.6%
Net margin-7.1%-18.1%-26.0%-40.1%-24.0%
Return on equity-7.2%-14.1%-29.0%-55.5%-21.0%
Return on assets-2.8%-6.3%-11.7%-18.4%-8.8%
Free cash flow yield0.9%-1.3%———
Revenue growth24.7%32.0%17.9%26.7%—
Earnings growth-51.1%-8.5%-23.5%111.9%—
Current ratio1.41x1.68x1.27x1.08x1.49x
Debt to equity0.15x0.07x0.00x0.00x0.00x
Equity ratio38.8%45.0%40.3%33.1%42.1%
Interest coverage-7.39x-24.63x-20.95x-41.53x-35.48x
R&D as a share of sales26.8%37.0%47.5%51.2%42.9%
Buybacks as a share of market value0.0%————

Growth per year

Compound annual rate

3 years5 years10 years
Revenue30.9%——
Operating income-26.6%——
Net income-26.2%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin52.3%52.6%——

Valuation history

At each fiscal year end

FY2025FY2024
Price to earnings-127.8-81.8
Price to sales9.214.9

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.